It can inhibit the binding of VEGF to its receptors VEGFR-1 and VEGFR-2 located on endothelial cells, so that VEGF loses its biological activity and reduces tumor angiogenesis, thus inhibiting tumor growth (Garcia et al., 2020). The gene discussed is KDR; the disease is neoplasm.